Press Releases

Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah

October 13, 2017:

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, Northeast Section in Savannah, October 12 at 4 pm.


Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12

October 10, 2017:

Nymox Pharmaceutical Corporation is pleased to report on the Symposium on Fexapotide Triflutate studies to be held at the Annual Meeting of the American Urological Association Northeastern Section, in Savannah GA this week.


Nymox Announces October 12 Symposium for Company’s BPH Drug at American Urological Association Meeting

September 25, 2017:

Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company’s new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, Northeast Section.


Nymox Announces Validation by the European Member States of European Marketing Authorization Application for Fexapotide Triflutate for Benign Prostatic Hyperplasia

September 14, 2017:

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the European Member States for Nymox’s Marketing Authorization Application (MAA) for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH, prostate enlargement) have accepted the Company’s MAA.


AUA Meeting in Florida September 16 Postponed Due to Hurricane

September 11, 2017:

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) The September 16 AUA Meeting in Amelia Island, Florida has been postponed due to the hurricane disaster in Florida.


Nymox Announces Private Placements of $3 Million

August 9, 2017:

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce recent completion of private placements with proceeds totaling US $3.0 million.


Nymox Announces Symposium for Company’s BPH Drug at American Urological Association Meeting in September

August 7, 2017:

Nymox  Pharmaceutical Corporation  is pleased to announce that an important large symposium and panel assessment of the Company’s new drug Fexapotide Triflutate will be held at the September meeting of the American Urological Association, MidAtlantic Section.


Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials

May 31, 2017:

Nymox Pharmaceutical Corporation is pleased to announce statistically significant clinical trial results showing that the Companys prostate enlargement (BPH) and prostate cancer drug Fexapotide Triflutate produced clinically important improvements in sexual function in first-line patients who received Fexapotide in the Companys U.S. long-term clinical trials.


NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT

May 10, 2017:

Nymox Pharmaceutical Corporation will hold a teleconference call for shareholders today May 10 at 4:30 EDT. The call in number is 1-888-424-8151 and the passcode is 7826703# (for Canada please use 1-888-465-5079).


NYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 EDT

May 8, 2017:

Following Nymoxs announcement of the Companys filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m. EST on Wednesday May 10, 2017.